⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ORIC News
Oric Pharmaceuticals, Inc. Common Stock
Form 8-K
sec.gov
ORIC
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
globenewswire.com
ORIC
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer
globenewswire.com
ORIC
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ORIC
Form 8-K
sec.gov
ORIC
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight
globenewswire.com
NVS
TLX
PFE
EXEL
LLY
XNCR
BTE
ORIC
MRK
ABBV
BMY
AZN
AMGN
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
ORIC
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
globenewswire.com
ORIC
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc. - ORIC
accessnewswire.com
ORIC
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc. - ORIC
accessnewswire.com
ORIC